Stay updated on Eli Lilly and Company Press Releases

Sign up to get notified when there's something new on the Eli Lilly and Company Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Eli Lilly and Company Press Releases page

  1. Check
    3 days ago
    Change Detected
    Summary
    The press release list now features Lilly’s agreement with Hims & Hers to expand access to its medicines and new data to be presented at ACR Convergence 2026. Earlier notices about ESMO oncology presentations and the third-quarter earnings announcement date have been removed.
    Difference
    8%
    Check dated 2026-11-07T15:15:31.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The press-release feed now features late-October 2026 announcements, including Lilly’s third-quarter results and raised guidance, retatrutide trial findings, a leadership transition, and the quarterly dividend. Earlier October releases on other clinical data and product updates have been replaced in the visible list.
    Difference
    8%
    Check dated 2026-10-31T15:38:36.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The press release listing now features announcements on investigational ovarian cancer treatment data, a new Richmond manufacturing facility, pediatric ulcerative colitis results, and Lilly’s oncology pipeline at ESMO 2026. Several earlier releases on diabetes, obesity, and dermatology study results no longer appear in the listing.
    Difference
    7%
    Check dated 2026-10-24T16:00:19.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The press release listing adds an October 15 announcement of Lilly’s third-quarter 2026 results and conference call, along with new Omvoh outcomes in ulcerative colitis and Crohn’s disease. It removes older releases comparing Zepbound with Wegovy HD and Foundayo with oral semaglutide.
    Difference
    6%
    Check dated 2026-10-17T15:54:52.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The press-release list adds announcements about Phase 3b findings for Taltz and Zepbound and Lilly’s dermatology presentations at Fall Clinical 2026. It removes earlier releases about Lilly’s access commitment for diabetes and obesity medicines and FDA approval of Olumiant for certain pediatric patients.
    Difference
    6%
    Check dated 2026-10-10T16:53:51.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The latest releases now cover Jaypirca’s expanded FDA indication, new findings for Lilly’s obesity and diabetes medicines, and an access commitment. Older releases about other drug approvals, clinical data, manufacturing, and corporate activity have dropped off the list.
    Difference
    7%
    Check dated 2026-10-03T16:45:51.000Z thumbnail image

Stay in the know with updates to Eli Lilly and Company Press Releases

Enter your email address, and we'll notify you when there's something new on the Eli Lilly and Company Press Releases page.